<DOC>
	<DOCNO>NCT00019240</DOCNO>
	<brief_summary>RATIONALE : Herpesvirus find Kaposi 's sarcoma lesion patient ; therefore possible herpesvirus role cause Kaposi 's sarcoma . Cidofovir antiviral drug act many type herpesvirus , may effective treatment Kaposi 's sarcoma . PURPOSE : Phase II trial study effectiveness cidofovir treat patient Kaposi 's sarcoma without HIV infection .</brief_summary>
	<brief_title>Antiviral Therapy Treating Patients With Kaposi 's Sarcoma With Without HIV Infection</brief_title>
	<detailed_description>OBJECTIVES : I. Assess antitumor activity intravenous cidofovir patient Kaposi 's sarcoma ( KS ) without human immunodeficiency virus ( HIV ) infection . II . Assess effect intravenous cidofovir load KS-associated herpesvirus/human herpesvirus-8 KS lesions peripheral blood mononuclear cell quantitative polymerase chain reaction . III . Assess toxicity cidofovir KS patient without HIV infection . IV . Assess effect cidofovir angiogenic cytokine relate pathogenesis KS . OUTLINE : All patient receive intravenous cidofovir weekly 2 week , every week 6 month . Patients complete partial response may continue treatment disease progression intervenes . PROJECTED ACCRUAL : Up 25 evaluable patient enter approximately 6 month least 2 response first 15 patient .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven Kaposi 's sarcoma ( KS ) HIV infection ( measure ELISA Western blot ) allow NCI pathology review require At least 5 measurable lesion require No prior local therapy indicator lesion Lesions evaluable noninvasive method No actively bleed critically locate KS immediate risk patient discretion Principal Investigator and/or Study Chairperson No pulmonary potentially acutely lifethreatening KS lesion PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : More 3 month Hematopoietic : Absolute neutrophil count least 750/mm3 Platelet count least 75,000/mm3 Hemoglobin least 11 g/dL ( 10 g/dL woman ) CD4 count great 50 cell per cubic millimeter Hepatic : Bilirubin great 1.5 time normal ( unless due Gilbert 's disease ) Patients protease inhibitor may bilirubin great 3.5 mg/dL ( direct bilirubin great 0.2 mg/dL ) AST/ALT great 75 IU/mL Alkaline phosphatase great 2.5 time normal Renal : Creatinine le 1.5 mg/dL Creatinine clearance ( calculate ) great 55 mL/min Proteinuria le 2+ Cardiovascular : No significant EKG abnormality Other : No actively lifethreatening infection At least 14 day since treatment serious infection No know clinically significant allergy probenecid sulfa No grade 3 bad clinical laboratory toxicity lymphopenia No medical condition precludes protocol treatment inform consent No second malignancy within 1 year except basal cell skin cancer No pregnant nursing woman Negative pregnancy test require fertile woman within 1 week prior entry , every 4 week study , 4 week last treatment Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : At least 1 week since treatment following : Diuretics Vidarabine Amphotericin B Aminoglycoside antibiotic Intravenous pentamidine Other know potentially nephrotoxic agent Other investigational agent antiherpesvirus activity At least 4 week since systemic local antiherpesvirus therapy mucocutaneous acyclovir cream At least 4 week since systemic therapy KS systemic cutaneous malignancy At least 1 month since discontinuation antiretroviral therapy Concurrent antiretroviral therapy allow provided dos follow , either alone combination , stable least 1 month prior entry : AZT ddC 3TC ddI d4T protease inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>classic Kaposi sarcoma</keyword>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
	<keyword>recurrent Kaposi sarcoma</keyword>
</DOC>